Skip to main content
ATTO
NASDAQ Life Sciences

Director Colin Walsh Buys $8.5M of Attovia Stock at $17, Sells $2.25M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$19.18
Mkt Cap
$874.205M
52W Low
$16.15
52W High
$22.79
52W Position info
19% above low
Off High info
16% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ATTO sits 19% above its 52-week low of $16.15 on light trading volume (0.4× avg).

Summary

Director Colin Walsh bought $8.5 million of Attovia stock at $17 per share, while also selling $2.25 million in market-making transactions. The purchase adds to insider accumulation following the IPO.


Key Events · Ownership and Investor Activity · ATTO

  • Director Buys $8.5M at IPO Price

    Colin Walsh purchased 500,000 shares at $17.00 on August 6, 2026, totaling $8.5 million, through Goldman Sachs entities.

  • Insider Accumulation Continues

    This purchase follows Frazier Life Sciences' $10 million purchase at $17.00 reported on August 6, 2026, indicating strong insider confidence.

  • Market-Making Sales Not Personal

    Walsh sold 105,807 shares for $2.25 million on August 5, but footnotes indicate these were Goldman Sachs market-making transactions, not personal divestment.

  • Preferred Stock Conversion

    Series B and C Preferred Stock converted into 2,435,632 common shares on August 6, correcting a prior Form 3 administrative error.


Analysis · ATTO · Life Sciences

Director Colin Walsh, through Goldman Sachs entities, purchased 500,000 shares at $17.00 on August 6, 2026, for $8.5 million, adding to the $10 million purchase by Frazier Life Sciences reported earlier. Walsh also sold 105,807 shares on August 5 for $2.25 million at prices between $20.84 and $22.19. The net effect is a significant accumulation by insiders, with Walsh's purchase representing a strong vote of confidence at the IPO price. The sale appears to be a market-making activity by Goldman Sachs, not a personal divestment, as noted in the footnotes.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ATTO was trading at $19.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $874.2M. The 52-week trading range was $16.15 to $22.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATTO - Latest Insights

ATTO
Nov 09, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.96
Real-time Price: $15.10 info
Change: -$0.860 (-5%) info
Market Cap: $690.259M info
ATTO
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $14.95
Real-time Price: $15.10 info
Change: +$0.150 (+1%) info
Market Cap: $690.259M info
ATTO
Sep 02, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.13
Real-time Price: $15.10 info
Change: -$8.03 (-35%) info
Market Cap: $690.259M info
ATTO
Sep 02, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $23.13
Real-time Price: $15.10 info
Change: -$8.03 (-35%) info
Market Cap: $690.259M info
ATTO
Aug 28, 2026, 5:38 PM EDT
Filing Type: 4/A
Importance Score:
7
Price at Filing: $20.70
Real-time Price: $15.10 info
Change: -$5.60 (-27%) info
Market Cap: $690.259M info